BIOCRYST PHARMACEUTICA

European Medicines Agency Grants PRIME Designation to BioCryst’s ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva

27 4 2022 07:00:00 提供 Nasdaq GlobeNewswire

BioCryst to Report First Quarter 2022 Financial Results on May 5

21 4 2022 07:00:52 提供 Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conference

11 4 2022 08:30:49 提供 Nasdaq GlobeNewswire

BioCryst Pauses Enrollment in BCX9930 Clinical Trials

08 4 2022 09:15:13 提供 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 4 2022 07:15:42 提供 Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

03 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

BioCryst Presents New Data Demonstrating Sustained Reductions in Attack Rates and Improvement in Quality of Life Among HAE Patients Following Long-Term Treatment with ORLADEYO® (berotralstat)

24 2 2022 07:00:02 提供 Nasdaq GlobeNewswire

BioCryst Reports Fourth Quarter and Full Year 2021 Financial Results and Upcoming Key Milestones

23 2 2022 07:00:01 提供 Nasdaq GlobeNewswire

BioCryst to Report Fourth Quarter 2021 Financial Results on February 23

09 2 2022 07:00:00 提供 Nasdaq GlobeNewswire